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It is well established that regions of low oxygen tension exist in
many human tumours and this can adversely affect their response
to radiotherapy, resulting in failure of local control (Overgaard 
et al, 1991). It has also been shown that hypoxic cells are resistant
to commonly used anti-cancer drugs because they tend to be fur-
thest from blood vessels and have slower rates of proliferation than
well-oxygenated cells (Kennedy, 1987). 
AQ4N (1,4-bis {[dimethylamino-N-oxide) ethyl]amino} 5,8-
dihydroxy-anthracene-9,10-dione) is a bioreductive drug that is
selectively toxic to hypoxic cells (Patterson, 1993; Hejmadi et al,
1996). We have shown that AQ4N enhances the anti-tumour effect
of both single-dose and fractionated radiation regimens, allowing a
50% reduction in radiation dose to achieve the same anti-tumour
effect (McKeown et al, 1995, 1996). More recently it has been
shown that AQ4N enhances the cytotoxicity of the widely used
chemotherapy agent cyclophosphamide, reducing by approxi-
mately 50% the dose of cyclophosphamide needed to achieve an
equivalent anti-tumour effect. In addition there was no significant
enhancement of the cytotoxicity of cyclophosphamide to the bone
marrow (Friery et al, 2000). AQ4N reduction involves cytochrome
P450 (cyp) mediated metabolism (Raleigh et al, 1998) as does
cyclophosphamide (Gervot et al, 1999). We therefore thought it
important to evaluate a second routinely used cytotoxic agent that
has no known enhancement linked to cyp-mediated pathways. The
most successful bioreductive drug available, tirapazamine
(SR4233; 3-amino-1,2,4-benzotriazine-1,4-dioxide), is currently
in use in phase II/III clinical trials in combination with, among
other agents, cisplatin. We therefore have chosen to test AQ4N in
combination with cisplatin in 3 murine tumours and have included 
tirapazamine with cisplatin as a comparator. 
MATERIALS AND METHODS 
Tumour models 
The T50/80 tumour is a poorly differentiated mammary carcinoma
that arose in a female B6D2F1 mouse (Moore, 1988). Tumours
were implanted intradermally (i.d.) on the rear dorsum of male
BDF mice aged 8–12 weeks using 0.05 ml of tumour brei prepared
from a donor mouse. Experiments were carried out using early
passages (4–12) of the tumour. The SCCVII (mouse squamous cell
carcinoma) and RIF-1 (mouse fibrosarcoma) tumours were main-
tained by the protocol of Twentyman et al (1980). Tumour cells 
(2 × 105 cells in 0.05 ml phosphate buffered saline [PBS]) were
implanted i.d. into male C3H mice aged 8–12 weeks. All animal
experiments were carried out in accordance with the UK Animals
(Scientific Procedures) Act 1986 and met the standards required
by the UKCCCR.
Drug preparation and administration 
AQ4N (15 mg/ml) was prepared in house (Patterson et al, 1993),
and made up in distilled water. Tirapazamine (1.75 mg/ml) was
obtained from Sanofi Research (PA, USA) as a lyophilized
powder, prepared in PBS and sonicated for 20 min to aid dissolu-
tion (McAleer et al, 1992). Cisplatin was purchased pre-dissolved
in water and diluted to form a 0.5 mg/ml solution. All drugs were
administered as a single intraperitoneal (i.p.) injection. The
maximum tolerated doses (MTDs) of individual and combination
treatments were selected using preliminary experiments and
published data, where available. 
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delay assay 
BDF mice were treated when the T50/80 tumour reached 6.5–7.5
mm geometric mean diameter (GMD). Tumours were measured 3
times weekly and the time taken to reach double its treatment
volume (VDT) was used as a measure of anti-tumour efficacy.
AQ4N (50–150 mg/kg) or tirapazamine (25 mg/kg, i.e. half the
MTD) were administered 30 min prior to cisplatin (4 mg/kg or 8
mg/kg, i.e. the MTD of this drug when administered alone).
Weight loss was routinely monitored as an indication of normal
tissue toxicity and did not fall below 15% for any drug combina-
tion. Tumour growth delay (TGD) was calculated by subtracting
the mean VDT for control tumours from that obtained after drug
exposure. The effect on tumour growth was assessed using the
analysis of variance (ANOVA) test. 
Measurement of the anti-tumour effect: in vivo/in vitro
clonogenic assay 
C3H mice bearing the SCCVII or RIF-1 tumours were treated
upon reaching a volume of 100–200 mm3. AQ4N (100 mg/kg) was
administered 30 min, 2.5 h or 6 h prior to cisplatin (4 mg/kg or
8 mg/kg) and tirapazamine (50 mg/kg) was administered 2.5 h
prior to cisplatin (4 mg/kg or 8 mg/kg). Anti-tumour efficacy was
measured, using the in vivo/in vitro clonogenic assay of Horsman
et al (1984). In outline 24 h after treatment tumours were excised,
minced and digested with an enzyme cocktail (6 mg DNase, 2 mg
collagenase and 2 mg pronase per 10 ml PBS) to produce a single
cell suspension. Pilot experiments were carried out by plating cells
at concentrations ranging from 500 to 1 × 107. This identified the
cell concentration that provided sufficient, but not confluent,
colonies to allow accurate counting in individual treatment groups.
Using the optimum concentrations, cells were plated in triplicate
and incubated in RPMI media with 10% fetal calf serum and 1%
penicillin/streptomycin at 37˚C in 95% air/5% CO2 for 12–14 d.
Colonies were fixed and stained with 0.4% crystal violet in 70%
methanol and scored by eye. Surviving fraction (SF) was calcu-
lated as the number of colonies counted, divided by the number of
cells plated for a given treatment, divided by the same fraction
determined for untreated control tumours. All data points repre-
sent the mean of 3 independent experiments. In each experiment,
2–3 tumours were used per treatment group so that a minimum of
6 and a maximum of 9 tumours were studied per group. 
Normal tissue–spleen colony assay 
The response of normal tissue to AQ4N and tirapazamine in
combination with cisplatin was evaluated in the bone marrow of
BDF mice by the spleen colony assay (Till and McCulloch, 1961).
Donor mice were injected i.p. with various doses and combina-
tions of the drugs (see results for details of doses and schedules).
Bone marrow cells were isolated from the femurs of the donor
mice 24 h later by flushing through twice with PBS (0.7 ml). Bone
marrow cells from 6 donor mice were pooled, counted and injected
into the tail vein of 6 recipient BDF mice, which had previously
been irradiated (24 h before) at 9 Gy. Pilot experiments had previ-
ously been carried out to determine the number of cells needed to
give a measurable number of colonies per spleen; this ranged from
1 × 104–1 × 107 cells per mouse. Mice were sacrificed 8 days later
and spleens were removed, placed in Bouin’s stain for 1.5 h and
stored in formalin (0.4%). Spleen colonies were counted by eye.
Surviving fraction was calculated as before and a Bonferoni
adjustment was applied to the data to show normal distribution.
Statistical significance was then determined by the unpaired
Student’s t-test. 
RESULTS 
Anti-tumour effects: T50/80 
AQ4N (50–150 mg/kg) alone showed very little effect on tumour
growth in the T50/80 tumour model with no difference between
the 3 doses administered. Combination of AQ4N (50 mg/kg) with
cisplatin (4 mg/kg) resulted in a significant (P = 0.0001) increase
in TGD of 4.5 d compared to 1.6 d obtained with cisplatin 
(4 mg/kg) alone (Figure 1). When the AQ4N dose was increased to
100 mg/kg the anti-tumour effect was significantly greater (P =
0.0001) than the effect of cisplatin at the single higher dose of 
8 mg/kg. This indicates that in the presence of AQ4N, the dose of
cisplatin may be reduced by half but still produces a greater effect
on the growth of the tumour. No additional improvement was
noted when the AQ4N dose was increased to 150 mg/kg.
Increasing the cisplatin dose to 8 mg/kg allowed a 3.2-d growth
delay. This was significantly increased to 7.5–9d  ( P = 0.0001)
when given in combination with AQ4N (50–150 mg/kg). 
Tirapazamine alone had little effect on tumour growth. The
combination of tirapazamine (25 mg/kg) with cisplatin (4 mg/kg)
resulted in a small tumour growth delay of 2.9 days, which was
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Table 1 The anti-tumour effect of AQ4N administered at three different
times prior to cisplatin in the SCCVII and RIF-1 tumour 
Surviving fraction 
Treatment Rif-1 SCCVII 
Cisplatin (8 mg/kg) 4.4 × 10-3 ± 0.001 1.1 × 10-3 ± 0.004 
AQ4N (30 min) < 1 × 10–6 < 1 × 10–6
AQ4N (2.5 h) < 1 × 10–6 < 1 × 10–6
AQ4N (6 h) < 1 × 10–6 < 1 × 10–6
Each drug was administered i.p. as a single dose. AQ4N (100 mg/kg) was
administered 30 min, 2.5 h or 6 h prior to cisplatin (8 mg/kg). The anti-tumour
effect was assessed by the clonogenic assay and the surviving fraction
calculated. Results are means +/– SE obtained from three individual
experiments (6–9 tumours per treatment group). 
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Figure 1 Interaction of the bioreductive drugs AQ4N with cisplatin (cDDP).
AQ4N (50–150 mg/kg) was administered as a single i.p. injection 30 min prior
to cisplatin (4–8 mg/kg) in the T50/80 murine tumour. Results were obtained
from 6–9 tumours per treatment group. Values are means ± SEstatistically greater than cisplatin administered alone (P = 0.038).
Higher dose combinations were not possible as preliminary exper-
iments showed unacceptable systemic toxicity beyond the doses
reported here. 
Anti-tumour effects: SCCVII 
Table 1 shows the pooled results (6–9 tumours) from 3 individual
experiments in which AQ4N (100 mg/kg) was administered to
tumour-bearing mice at various times prior to cisplatin (8 mg/kg).
Figure 2 shows the results obtained when AQ4N was administered
30 min prior to cisplatin. Cisplatin at its highest dose produced
over 2 logs of cell kill; this was enhanced by at least a further 4–5
logs when AQ4N was administered prior to cisplatin. The values
plotted are an underestimation since this level of cell killing was at
the limits of detection of the clonogenic assay. Administration of
AQ4N at a range of times (30 min, 2.5 h, 6 h) prior to cisplatin had
no effect on the efficacy of the drug interactions, with all 3 time
schedules producing no colonies (Table 1). Tirapazamine (50 mg/-
kg) administered 2.5 h prior to cisplatin (8 mg/kg) increased the
anti-tumour effect by a further log in cell killing as compared to
cisplatin alone. 
Anti-tumour effects: RIF-1 
An 8 mg/kg dose of cisplatin administered to C3H mice bearing the
RIF-1 tumour produced a cell kill of 2.5 logs (Figure 3), a slightly
greater effect than observed in the SCCVII tumour. This killing was
increased by at least a further 3 logs when AQ4N (100 mg/kg) was
administered 30 min and 6 h prior to cisplatin (8 mg/kg) (Table 1).
AQ4N (100 mg/kg) in combination with the lower dose of cisplatin
(4 mg/kg) increased the cell kill by 1 log. When tirapazamine (50
mg/kg) was administered 2.5 h prior to cisplatin at doses of both 4
mg/kg and 8 mg/kg, an additional log of cell kill was obtained at the
higher cisplatin dose. Both AQ4N and tirapazamine displayed very
little cytotoxicity towards SCCVII and RIF-1 tumour cells when
administered alone (Figure 2, Figure 3). 
Normal tissue toxicity 
In order to evaluate the therapeutic potential of AQ4N, a spleen
colony assay was used to determine the bone marrow toxicity of
the drug when given in combination with cisplatin. From the dose
response curve it can be seen that AQ4N is only slightly marrow
toxic at the highest dose tested (Figure 4). Administering AQ4N
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Figure 2 Anti-tumour efficacy of the bioreductive drugs AQ4N or
tirapazamine (TPZ) in combination with cDDP in the SCCVII murine tumour.
AQ4N (100 mg/kg) was administered as a single i.p. injection 30 min prior to
cDDP (8 mg/kg). TPZ (50 mg/kg) was administered 2.5 h prior to cDDP
(8 mg/kg). Tumours were excised 24 h after treatment and clonogenic cell
survival measured. Each data point represents the mean ± SE for 3
experiments (6–9 tumours per treatment group)
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Figure 3 Anti-tumour effect of AQ4N or tirapazamine (TPZ) in combination
with cDDP in the RIF-1 model. AQ4N (100 mg/kg) was administered as a
single i.p. injection 30 min prior to cDDP (4 mg/kg or 8 mg/kg). TPZ
(50 mg/kg) was administered 2.5 h prior to cDDP (4 mg/kg or 8 mg/kg).
Tumours were excised 24 h after treatment and clonogenic cell survival
measured. Each data point represents the mean ± SE for 3 experiments
(6–9 tumours per treatment group)
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Figure 4 The myelotoxic effect of AQ4N, TPZ and cDDP. BDF mice were
dosed i.p. with AQ4N (50–100 mg/kg), TPZ (12.5–50 mg/kg) and cDDP
(2–8 mg/kg). The survival of bone marrow cells was assessed by the spleen
colony assay. In order to allow drug doses to be plotted on the same scale,
drug doses are plotted with the highest dose used designated as HD. Results
are the mean ± SE for 6 mice(100 mg/kg) 6 h prior to cisplatin (4 mg/kg or 8 mg/kg) did 
not significantly increase the toxicity caused by treatment with
cisplatin alone (P = 0.313 and 0.671, respectively), (Figure 4 
and 5). AQ4N (100 mg/kg) given 30 min prior to cisplatin 
(8 mg/kg) resulted in a small increase in toxicity to bone marrow
cells, although it was not statistically significant (P = 0.073).
Tirapazamine (25 mg/kg) alone showed a greater increase in toxi-
city as compared to AQ4N. However it did not potentiate cisplatin-
induced bone marrow toxicity at 8 mg/kg, although a small effect
was observed with 4 mg/kg (P = 0.689) (Figure 5). 
DISCUSSION 
Our previous studies have shown that AQ4N causes a major
increase in the anti-tumour effect of cyclophosphamide in 3
tumour models, with only a limited increase in bone marrow toxi-
city (Friery et al, 2000). In this study the anti-tumour effect of
AQ4N in combination with the chemotherapy agent cisplatin was
investigated in the same 3 models, T50/80, SCCVII and RIF-1
murine tumours. 
In our initial series of experiments using the T50/80 model, the
combination of cisplatin (4 mg/kg or 8 mg/kg) with AQ4N
resulted in an enhanced anti-tumour effect at both doses tested 
(P = 0.0001) (Figure 1). AQ4N (50 and 100 mg/kg) with cisplatin
(4 mg/kg) produced an effect ~1.5 times greater than a single 
8 mg/kg dose of cisplatin alone, showing that in the presence of
AQ4N, the dose of cisplatin can be reduced by 50% to give an
equivalent anti-tumour effect. The combination of AQ4N with the
higher cisplatin dose (8 mg/kg) produced an effect that was 
greater than additive with all AQ4N doses tested and was about 
2 times greater than the effect achieved with cisplatin alone.
Unfortunately, we could not evaluate an equivalent dose for
cisplatin alone since 8 mg/kg of cisplatin is the MTD for this
agent. Tirapazamine (25 mg/kg) in combination with 4 mg/kg
cisplatin produced a slightly less than additive effect, although it
was still equivalent to a single 8 mg/kg dose of cisplatin alone.
This anti-tumour effect is probably understated since the timing
schedule was not optimized for tirapazamine in this tumour model.
It was also necessary to limit the tirapazamine dose in this assay
to 25 mg/kg as systemic toxicity, as measured by weight loss,
precluded by using higher dose combinations (data not shown). 
It should be noted that cisplatin had only a small effect on
T50/80 tumour growth, although this can be enhanced signifi-
cantly with AQ4N. We therefore also investigated drug combina-
tions in 2 further tumour models, including the RIF-1 tumour,
which has been shown to be sensitive to combinations of tirapaza-
mine and cisplatin (Dorie and Brown, 1993; Siemann and
Hinchman, 1998). The present data demonstrates that AQ4N can
significantly increase tumour cell killing observed in both the
SCCVII and RIF-1 tumour models when administered prior to
cisplatin (8 mg/kg). There was a surviving fraction of less than 1 in
106 cells in both model systems. AQ4N alone produced few cyto-
toxic effects, supporting the claim that it is selectively toxic
towards hypoxic cells. 
Tirapazamine was administered 2.5 h prior to cisplatin since this
was reported to be the optimum time schedule for this combination
(Dorie and Brown, 1993). An increase of 1 log of cell kill was
observed for both the SCCVII and RIF-1 model systems; this is
significantly less than that reported by Dorie and Brown (1993,
1997), who showed an enhancement of 3 logs in cell kill in both
models. The explanation for this discrepancy is not immediately
apparent, although scheduling of tirapazamine is thought to be crit-
ical. However, our results clearly show that both bioreductive drugs
can enhance the anti-tumour effect of cisplatin. Unlike tirapaza-
mine, the enhancement of cisplatin cytotoxicity by AQ4N was not
time dependent. AQ4N produced an equally impressive anti-
tumour effect when given 30 min, 2.5 h, or 6 h prior to cisplatin
(Table 1). This is probably due to the fact that once AQ4N under-
goes enzymatic reduction to its cytotoxic metabolite, AQ4, it binds
avidly to DNA (Smith et al, 1997). In contrast, Dorie and Brown
have shown that the interaction between tirapazamine and cisplatin
was no more than additive when the two compounds were given
simultaneously and the anti-tumour effect was maximal when tira-
pazamine was administered 2.5 h prior to cisplatin. 
The mechanism for the enhancement of the anti-tumour effect
of cisplatin with either bioreductive drug can be explained in a
similar way to the enhancement of radiation. Bioreductive drugs,
when administered alone will kill hypoxic cells within the tumour
but will have little effect on the overall tumour growth. This is only
seen if a standard oxic cell cytotoxin is combined with a bioreduc-
tive agent. The advantage of killing both cell populations concur-
rently is clearly seen in the combination studies. 
The anti-tumour effect of AQ4N in combination with cisplatin
is made more impressive by the normal tissue toxicity results. The
spleen colony assay was selected to test normal tissue toxicity
since AQ4N and its cytotoxic metabolite, AQ4, are close
analogues of the routinely used chemotherapy agent mitoxantrone
(Patterson, 1993). Since one of the major sites of mitoxantrone
toxicity is the bone marrow, it is not unreasonable to suggest that
this might be the limiting toxicity for AQ4N. In fact, AQ4N
(50–200 mg/kg) as a single agent showed very little bone marrow
toxicity. In addition toxicity was less than that observed for tira-
pazamine, which was also modest. Cisplatin, although not consid-
ered to be a strongly myelotoxic agent, was more myelotoxic than
both bioreductive drugs, with the highest dose of cisplatin
resulting in a cell kill of 1 log. Siemann and Hinchman (1998),
using an in vivo/in vitro bone marrow assay, reported a cell kill for
cisplatin in the same range. 
628 R Gallagher et al
British Journal of Cancer (2001) 85(4), 625–629 © 2001 Cancer Research Campaign
0
PSA-mRNA positive
(n=24)
negative
(n=22)
p < 0.001
1
2
3
N
u
m
b
e
r
 
o
f
 
c
a
n
c
e
r
 
p
o
s
i
t
i
v
e
 
c
o
r
e
s
4
5
6
Figure 5 The effect of AQ4N and TPZ on the bone marrow toxicity of
cDDP. BDF mice were dosed i.p. with AQ4N (100 mg/kg) 30 min or 6 h prior
to cDDP (4 mg/kg or 8 mg/kg). TPZ (25 mg/kg) was administered 2.5 h prior
to cDDP (4 mg/kg or 8 mg/kg). The survival of bone marrow cells was
assessed by the spleen colony assay. Results are mean ± SE for 6 miceThe administration of AQ4N (100 mg/kg) 6 h prior to cisplatin
at both doses of 4 mg/kg and 8 mg/kg did not enhance the toxicity
caused by cisplatin alone, suggesting that the 2 drugs do not have
overlapping toxicities in this model. When AQ4N was adminis-
tered 30 min prior to cisplatin, there was a small enhancement 
(P = 0.073) of bone marrow toxicity at 8 mg/kg of cisplatin. This
suggests that it might be advantageous to separate the administra-
tion of AQ4N and cisplatin by an interval of possibly of more than
2 h. Compared to the enhancement in the anti-tumour efficacy 
(> 4 logs) there was only a small enhancement of bone marrow
toxicity (~0.3 logs) and this was only observed within the 30 min
time schedule. AQ4N shows little schedule dependence with
respect to its anti-tumour effect and thus AQ4N clearly enhances
the therapeutic efficacy of cisplatin in these models. Tirapazamine
(25 mg/kg) appeared to be slightly more toxic towards bone
marrow cells than AQ4N. Like AQ4N, tirapazamine did not
enhance the myelotoxicity of cisplatin at either dose examined,
supporting the findings of Holden et al (1992) and Siemann and
Hinchman (1998). 
In conclusion, this study demonstrates that AQ4N can potentiate
the anti-tumour effect of cisplatin. The remarkable increase in anti-
tumour effect combined with the lack of bone marrow toxicity
translates into a therapeutic gain. This supports the view that
AQ4N is a bioreductive drug with major clinical potential, since it
can enhance the anti-tumour effect of cisplatin, cyclophosphamide
and radiation with little or no enhancement of bone marrow 
toxicity. 
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